Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial
第一作者单位：[1]Capital Med Un, Gen Surg, Beijing Friendship Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Yang Y.,Pang K.,Zhang Z..Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial[J].ANNALS OF ONCOLOGY.2022,33(7):S739-S739.doi:10.1016/j.annonc.2022.07.1868.
APA：
Yang, Y.,Pang, K.&Zhang, Z..(2022).Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial.ANNALS OF ONCOLOGY,33,(7)
MLA：
Yang, Y.,et al."Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial".ANNALS OF ONCOLOGY 33..7(2022):S739-S739
医学